RAMP 301 Eligibility Criteria

Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy

Co-existing high-grade ovarian cancer or another histology

Prior treatment with avutometinib, defactinib, or other FAK inhibitors

History of prior malignancy with recurrence <3 years from the time of enrollment

Major surgery within 4 weeks

Symptomatic brain metastases or spinal cord compression

An active skin disorder that has required systemic therapy within one year of signing informed consent

History of medically significant rhabdomyolysis

For subjects with prior MEK exposure, Grade 4 toxicity deemed related to the MEK inhibitor

Concurrent ocular disorders

Concurrent heart disease or severe obstructive pulmonary disease

Subjects with the inability to swallow oral medication

Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy